Does Wegovy actually work for weight loss?

What 'working' actually means, and a common misconception worth clearing up

One thing that trips people up early: Wegovy is not a medicine that produces dramatic results in the first few weeks. The treatment starts at 0.25mg, a dose whose job is to let your body adjust rather than to drive weight loss directly. Many people feel underwhelmed at first, and some conclude too early that it is not working. The evidence from clinical trials only becomes meaningful at the maintenance dose of 2.4mg, reached after a titration period of around four to five months. Understanding this timeline changes how you read your own progress.

So what does 'working' look like when the medicine reaches its full dose? In the STEP 1 trial, published in the New England Journal of Medicine, participants on semaglutide 2.4mg lost a mean of around 14.9% of their starting body weight over 68 weeks, compared with about 2.4% for those on placebo. More than two-thirds of participants lost at least 10% of their body weight. Those are consistent, population-level findings, and if you are wondering whether Wegovy really works beyond the trial data, individual results sit above and below the average, which is exactly why a personal clinical assessment matters before starting.

For a broader look at the biology driving those numbers, how semaglutide acts on appetite and metabolism is worth reading alongside this page.

The factors that shape whether Wegovy works for you specifically

Three things tend to separate people who see strong results from those who see modest ones. First, adherence to the dose titration schedule, missing injections or staying on a lower dose longer than advised reduces exposure to the medicine's full effect. Second, the lifestyle component. Wegovy's licence explicitly states it is used alongside a reduced-calorie diet and increased physical activity; the trial participants had structured support for both. The medicine reduces appetite considerably, but the body still responds better when dietary quality and movement are part of the picture.

Third, individual biology. GLP-1 receptor sensitivity varies. Some people experience a strong appetite-suppressing response even at lower doses; others need more time at the maintenance dose before weight loss accelerates. There is also evidence that weight regain is likely if treatment stops without the underlying behaviours being sustained, a separate question covered in detail on whether Wegovy's effects plateau or fade over time.

It is also worth knowing that Wegovy is not licensed for everyone. The UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A prescriber will look at your full medical history, not just your BMI, and some people also notice physical changes during treatment, including what Wegovy does to the hands, certain conditions and medicines affect suitability.

NHS access versus private prescription, what that means for getting started

Wegovy is available on the NHS, but access is strictly phased and generally requires referral to a specialist weight management service with waiting lists that can stretch for months. NICE's appraisal of semaglutide (TA875) recommends it for adults with a BMI of 35 or above and at least one weight-related comorbidity, used within a multidisciplinary specialist service for a maximum of two years. Ethnic-background BMI thresholds are 2.5 kg/m² lower throughout.

For people who do not meet the NHS criteria or prefer not to wait, a private prescription through a regulated online pharmacy is the alternative. If you are weighing up how Wegovy is priced across UK providers, the honest point is that any legitimate quote should include a clinical consultation and a prescription, not just the pen itself. A prescriber reviews your case before any treatment is issued, that step is part of the legal requirement, not an optional extra.

At nume, consultations are reviewed by a GPhC-registered Independent Prescriber the same day, and treatment, once approved, is dispatched the same day for free next-working-day delivery. You can read more about the treatment options we offer if you are still deciding which medicine fits your situation.

Side effects and what they mean for sticking with treatment

The most common side effects are gastrointestinal (nausea, vomiting, constipation and diarrhoea) and they are most noticeable in the early weeks after starting or after a dose increase. For most people they settle. They are also the primary reason some people stop treatment before reaching the maintenance dose, which means they never experience the medicine's full effect.

Eating smaller portions, staying hydrated and avoiding fatty or rich foods at the start makes a practical difference to tolerability. The NHS semaglutide medicines page lists the full side-effect profile alongside guidance on which symptoms warrant prompt medical attention. Rare but serious reactions, including signs of pancreatitis such as severe stomach pain radiating to the back, require urgent care. Reporting any suspected side effects through the MHRA Yellow Card scheme helps build the post-market safety picture for everyone on this medicine.

If you have more questions about how the medicine behaves once it is in your system, a closer look at semaglutide's mechanism covers the pharmacology in plain language. And when you are ready to talk through whether this is the right option for your situation, speaking to our prescribers is the place to start.